Tenet Healthcare Corp. ((THC)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tenet Healthcare’s latest earnings call struck a confident tone, with management highlighting double‑digit EBITDA growth, margin expansion, and strong execution across both its USPI ambulatory business and hospital segment. Solid free cash flow and active balance sheet management underpinned that optimism, even as executives acknowledged looming policy headwinds and a wider‑than‑usual guidance range for 2026.
Robust 2025 Revenue and Margin Expansion
Tenet reported 2025 net operating revenues of $21.3 billion and consolidated adjusted EBITDA of about $4.57 billion, translating to roughly 14% year‑over‑year growth. The company’s full‑year adjusted EBITDA margin improved to 21.4%, expanding by about 200–210 basis points and underscoring sustained operating discipline.
Fourth‑Quarter Finish Tops Prior Year
In the fourth quarter, Tenet generated $5.5 billion in net operating revenues and $1.183 billion in consolidated adjusted EBITDA, up 13% from the prior year period. Q4 adjusted EBITDA margin also landed at 21.4%, demonstrating that margin gains are holding as the company exits 2025.
USPI Delivers Scale and High Margins
USPI remained a key growth engine, with adjusted EBITDA growing to roughly $2.026 billion in 2025 and Q4 EBITDA up 9% as margins reached a robust 40.5%. Same‑facility system‑wide revenues climbed about 7.2% in Q4, driven by a 5.5% increase in net revenue per case and 1.6% higher case volumes, while total joint replacements in ASCs delivered double‑digit same‑store volume growth for the year.
Ongoing Investment in Ambulatory Expansion
Management emphasized reinvestment in USPI, noting nearly $350 million deployed in 2025 and the addition of 35 facilities. Looking ahead, Tenet described a strong M&A and de novo pipeline and set a USPI acquisition target of roughly $250 million in 2026, signaling continued focus on high‑margin outpatient growth.
Hospital Segment Builds Earnings Momentum
The hospital segment also posted strong results, with adjusted EBITDA rising about 16% in 2025 to approximately $2.54 billion. Same‑hospital revenue per adjusted admission increased 5.3% for the year and jumped 7.5% in Q4, as Tenet leans into higher‑acuity service lines and allocates more growth capital to these areas.
Cost Controls and Labor Efficiency Improve
Tenet’s cost structure continued to improve, with consolidated salary, wages, and benefits falling to 40.2% of net revenues in Q4, an improvement of roughly 110 basis points versus last year. Contract labor expense has been reduced to 2.1% of total salary, wages, and benefits, indicating tighter labor management and a more sustainable staffing model.
Free Cash Flow Strengthens Balance Sheet
The company generated $2.53 billion in free cash flow for 2025, including $367 million in Q4 alone, bolstering its financial flexibility. Tenet ended the year with $2.88 billion in cash, no borrowings on its credit line, leverage of about 2.25x EBITDA, and no major debt maturities until late 2027.
Share Repurchases Enhance Equity Value
Capital returns were another focal point, as Tenet repurchased 8.8 million shares for $1.386 billion in 2025, including 943,000 shares for $198 million in Q4. Since 2022, the company has retired roughly 22% of its outstanding shares for about $2.5 billion and plans to continue opportunistic buybacks, citing attractive valuation multiples.
Conifer Deal Unlocks Cash and Reduces Obligations
Management highlighted a recently completed Conifer‑related transaction that retired around $885 million of obligations and involved repurchasing 23.8% of JV equity for $540 million. The deal is expected to accelerate approximately $1.9 billion of cash flow over three years and deliver an estimated after‑tax net present value benefit of about $1.0–$1.1 billion, framed as a clear value‑creation move.
Exchange Tax Credit Expiration Pressures 2026
A major overhang is the expiration of enhanced exchange premium tax credits, where Tenet assumes roughly a 20% reduction in exchange enrollment in 2026. Management estimates this shift will create about a $250 million drag on adjusted EBITDA, hitting the hospital segment hardest through lower volumes and a weaker payer mix.
Coverage Shifts Add Volume and Payer Mix Risk
Executives stressed that actual enrollment and coverage “effectuation” remain uncertain, with about 10–15% of exchange members assumed to move to other commercial plans. Depending on how patients transition, Tenet could see meaningful swings in volumes, payer mix, and uninsured or bad‑debt exposure, leaving a wide band of potential outcomes.
Normalized Comparisons Temper Apparent Growth
Tenet reminded investors that 2025 benefited from $148 million of prior‑year supplemental Medicaid payments that will not repeat, calling this a normalizing item for 2026 comparisons. The company also flagged a $40 million one‑time Conifer revenue adjustment in 2026, which together complicate simple year‑over‑year EBITDA growth readings.
Hospital Volume Growth Slows from Prior Trends
On the volume side, same‑hospital inpatient adjusted admissions were flat in Q4 2025, with weaker‑than‑expected respiratory season activity dampening growth. For 2026, Tenet is guiding to only 1–2% growth in same‑hospital adjusted admissions, a notable deceleration from past years and a reminder that the hospital recovery is maturing.
Wide Guidance Range Signals Visibility Challenges
Reflecting these uncertainties, Tenet set a relatively wide 2026 adjusted EBITDA guidance range of $4.485 billion to $4.785 billion. Management explicitly tied that spread to downside risk around exchange enrollment and policy outcomes, signaling that while the core business is performing well, forecasting precision is limited.
Quarterly Noise to Cloud Early‑Year Trends
The company also cautioned that quarter‑to‑quarter comparisons will be noisy, especially in Q1 2026, given the timing of prior‑period items and the Conifer revenue adjustment. Investors were told to expect Q1 to represent about 24% of full‑year consolidated EBITDA, with USPI’s first quarter at roughly 22% of its annual EBITDA.
Guidance and Outlook Point to Underlying 10% EBITDA Growth
For 2026, Tenet guided consolidated net operating revenues to $21.5–$22.3 billion and adjusted EBITDA to $4.485–$4.785 billion, with USPI expected at $2.13–$2.23 billion and hospitals at $2.355–$2.555 billion. Management projects same‑facility USPI revenue growth of 3–6% and 1–2% same‑hospital adjusted admissions growth and, after backing out exchange headwinds and normalizing items, expects underlying adjusted EBITDA to rise about 10% at the midpoint, supported by $2.5–$2.8 billion of adjusted free cash flow and continued USPI M&A and buybacks.
Tenet’s earnings call painted a picture of a company executing well operationally while navigating real policy and demand uncertainties. Investors are left with a mixed but generally constructive setup: strong margins, cash generation, and capital returns on one side, and policy risk, slower hospital volume growth, and wide guidance bands on the other, making 2026 a year where stock performance may hinge on how those external variables ultimately break.